Chugai obtains exclusive rights from Roche to develop & market ROS1/TRK inhibitor entrectinib in Japan

Chugai Pharmaceutical Co., Ltd has entered into a license agreement with F. Hoffmann─La Roche, Ltd. for the ROS1/TRK inhibitor entrectinib (Development Code: RG6268), which is under development for tumors that harbor ROS1 or NTRK fusions.

More From BioPortfolio on "Chugai obtains exclusive rights from Roche to develop & market ROS1/TRK inhibitor entrectinib in Japan"